Press Releases
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market
